Semax (Met-Glu-His-Phe-Pro-Gly-Pro)

Overview

Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH 4-10), developed by Russian researchers as part of a peptide neuroscience research program distinct from the parent hormone’s endocrine activity. Peptide Factory supplies Semax as a lyophilized powder for laboratory and in vitro research.

Research Background

The Semax sequence (Met-Glu-His-Phe-Pro-Gly-Pro) retains the core Met-Glu-His-Phe motif of ACTH(4-10) while adding a Pro-Gly-Pro extension, a modification studied for its effect on peptidase resistance and central nervous system research applications. Mechanistic research has focused on Semax’s interaction with the BDNF/TrkB signaling pathway and its effect on monoamine neurotransmitter systems in animal models.

Studied Applications

Laboratory research on Semax has examined:

• Neurotrophic factor research — rodent studies investigating changes in BDNF expression in the hippocampus and cortex following Semax administration in experimental protocols.
• Cognitive and attentional research models — behavioral paradigms assessing learning, memory consolidation, and attention in animal models.
• Neuroprotection research — in vivo models of induced cerebral ischemia have been used to characterize Semax’s effects on neuronal survival markers.

All findings referenced here derive from preclinical/laboratory research; no claims of clinical safety or efficacy in humans are made or implied.

Storage & Handling

Store lyophilized Semax at -20°C, protected from light and moisture. See storage and handling guidance for reconstitution protocols.

References

• Ashmarin, I. P. et al. Structural-functional studies of ACTH(4-10) analogs, Institute of Molecular Genetics RAS.
• Dmitrieva, V. G. et al. Semax and BDNF gene expression in rodent brain tissue.
• Shadrina, M. I. et al. Neuroprotective peptide research in cerebral ischemia models.

For Research Use Only — Not for Human Consumption.